Frazier Life Sciences β 2021 Investments
4 investments dated 2021 Β· listed companies and verified rows first Β· show all
South San Francisco, US
Board seatJames TopperJames W. BrushΒ· per SEC Form D
Early-stage company from the Archer Seed Fund that received follow-on funding in outside-led rounds.
Philadelphia, US
Mark Hefferman(Executive Officer, Director)Tadataka Yamada(Director)Nancy Hong(Director)
BoardCindy Cole(Director)
Board seatPatrick HeronAditya KohliΒ· per SEC Form D
Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.
BiotechHealthtechGermantown, US
Gi-Hyeok Yang(Director)Carole Welsch(Executive Officer)William L. Rust(Executive Officer, Director, Promoter)Roy Arup(Director)Bernie Treidl(Director)
Board seatJames N. TopperΒ· per SEC Form D Β· $40M raise Β· filed Feb 2021
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Fan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)Jeffrey Bluestone(Executive Officer, Director, Promoter)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.